Better Buy: Bluebird Bio Vs. Novavax
If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop catastrophically in recent years. Bluebird's stock is down by 91% in the past three years, while Novavax's has declined by 97%.
The market doesn't have much faith in either company, but if they can turn things around, opportunistic investors who initiate positions now could significantly beat the market over the long run. Which of these two biotechs should aggressive, contrarian investors consider adding to their portfolios? Let's find out.
Source Fool.com
Novavax Inc. Aktie
4,00 €
4,49 %
Unentschieden bei Novavax Inc.: 3 Buy- stehen 2 Sell-Einschätzungen gegenüber.
Die Community prognostiziert für Novavax Inc. ein Kursziel von 12 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 4.0 € bedeutet.
